CA2928759A1 - Compositions and methods for administration of an enzyme to a subject's airway - Google Patents

Compositions and methods for administration of an enzyme to a subject's airway Download PDF

Info

Publication number
CA2928759A1
CA2928759A1 CA2928759A CA2928759A CA2928759A1 CA 2928759 A1 CA2928759 A1 CA 2928759A1 CA 2928759 A CA2928759 A CA 2928759A CA 2928759 A CA2928759 A CA 2928759A CA 2928759 A1 CA2928759 A1 CA 2928759A1
Authority
CA
Canada
Prior art keywords
composition
plasminogen activator
solution
subject
nebulized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928759A
Other languages
English (en)
French (fr)
Inventor
Robert O. Williams, Iii
Steven Idell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53005414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2928759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2928759A1 publication Critical patent/CA2928759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2928759A 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway Abandoned CA2928759A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899739P 2013-11-04 2013-11-04
US61/899,739 2013-11-04
PCT/US2014/063784 WO2015066664A2 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Publications (1)

Publication Number Publication Date
CA2928759A1 true CA2928759A1 (en) 2015-05-07

Family

ID=53005414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928759A Abandoned CA2928759A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Country Status (11)

Country Link
US (2) US20160279209A1 (enExample)
EP (1) EP3065705A4 (enExample)
JP (1) JP2016535782A (enExample)
KR (1) KR20160078986A (enExample)
CN (1) CN105764488A (enExample)
AU (1) AU2014341862A1 (enExample)
CA (1) CA2928759A1 (enExample)
CL (1) CL2016001062A1 (enExample)
MX (1) MX2016005720A (enExample)
PE (1) PE20160789A1 (enExample)
WO (1) WO2015066664A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4438044A3 (en) 2013-03-15 2024-12-04 Board of Regents, The University of Texas System Peptide fttftvt for use in treating fibrosis
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5302390A (en) 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
CN1620334A (zh) * 2001-12-21 2005-05-25 环境清洁技术公司 锰氧化物的预处理与再生
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
US20070157931A1 (en) 2005-07-11 2007-07-12 Richard Parker System and method for optimized delivery of an aerosol to the respiratory tract
EP1962869B1 (en) * 2005-12-21 2013-03-20 SolAeroMed Inc. Treatment of respiratory diseases
SI22865A (sl) 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptid uroaktivin kot aktivator encima urokinaze
JP2012509941A (ja) * 2008-11-26 2012-04-26 ファイブ・プライム・セラピューティクス，インコーポレイテッド Ｓｅｒｐｉｎｅ２によるコラーゲンおよび平滑筋アクチンの発現を調節するための組成物および方法
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction

Also Published As

Publication number Publication date
US20190255157A1 (en) 2019-08-22
PE20160789A1 (es) 2016-08-17
EP3065705A2 (en) 2016-09-14
WO2015066664A2 (en) 2015-05-07
KR20160078986A (ko) 2016-07-05
AU2014341862A1 (en) 2016-05-19
CN105764488A (zh) 2016-07-13
US11033611B2 (en) 2021-06-15
MX2016005720A (es) 2016-11-25
CL2016001062A1 (es) 2017-01-13
US20160279209A1 (en) 2016-09-29
JP2016535782A (ja) 2016-11-17
WO2015066664A3 (en) 2015-09-17
EP3065705A4 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
US11905336B2 (en) Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
US11033611B2 (en) Compositions and methods for administration of an enzyme to a subject's airway
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
WO2022009081A1 (en) Drug for use against the novel coronavirus disease, covid-19
JP2007524607A (ja) 凝固因子の吸入による血友病処置
JP2007524607A6 (ja) 凝固因子の吸入による血友病処置
US7807639B2 (en) Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US20220160814A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
KR102664833B1 (ko) 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
US20180140547A1 (en) Compositions and methods for administration of an enzyme to a subject's airway
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
BRPI0613137A2 (pt) administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
JP7616697B2 (ja) ウイルス性肺炎を治療する方法及び薬剤
US20250108068A1 (en) Compositions and methods for alleviating pulmonary ailments
Vanbever Optimization of dry powder aerosols for systemic drug delivery
RU2396086C2 (ru) Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
HK40084754A (en) Method and drug for treating viral pneumonia
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment
ZA200702428B (en) Methods for treating local trachéal, bronchial or alveolar bleeding or hemoptysis
WO2014071005A1 (en) Methods and compositions using neuroprotective steroids and thrombolytic agents
HK1104970B (en) Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191105